• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » St. Jude-backed Spinal Modulation enrolls 1st patient in pain management study

St. Jude-backed Spinal Modulation enrolls 1st patient in pain management study

September 4, 2013 By Ingrid Mezo

ACCURATE trial of Axium neurostimulator to treat chronic pain kicks off

California-based Spinal Modulation’s, a spinal device maker backed by industry titan St. Jude Medical (NYSE:STJ), enrolled the 1st patient in the ACCURATE clinical trial to evaluate the safety and effectiveness of the Axium neurostimulator system for the treatment of chronic lower limb pain.

Axium, which holds a CE Mark in Europe and TGA approval in Australia, is an implantable medical device that delivers mild electrical pulses to the dorsal root ganglion, a specific branch of the spinal cord which contains the primary sensory neurons that transmit pain signals from the peripheral nerves to the brain.

"Chronic post-surgical pain is a major unaddressed need," study co-lead and International Neuromodulation Society president elect Dr. Tim Deer said in prepared remarks on behalf of the company. "Up to 35% of patients who undergo hernia surgery and 50 to 85% of patients who undergo amputations suffer from chronic post-surgical pain. The Axium Neurostimulator System can potentially expand treatment options for this large under-served patient group."

The prospective, randomized, multi-center, controlled ACCURATE study will span up to 25 U.S. medical centers, targeting up to 152 patient with chronic lower limb pain caused by Complex Regional Pain Syndrome or nerve damage, according to a press release.

"The recently published European data from a non-randomized study are promising – 78% of patients experienced pain relief in the lower limbs," principal investigator Dr. Eric Grigsby said on behalf of Spinal Modulation. "I am excited to be the 1st in the country to participate in this important clinical trial."

If successfully cleared through E.U. and U.S. regulators, the technology could be the next pain management in St. Jude’s portfolio. St. Jude in June branded Spinal Modulation as its territory with a $40 million equity investment that gave St. Jude international distribution rights and an exclusive option to acquire the company down the road.

St. Jude nabbed immediate distribution rights for the Axium system, as well as longer-term acquisition rights that allow St. Jude to nab Spinal Modulation for up to $300 million, with additional revenue-based payment milestones, once Spinal Modulation achieves U.S. commercialization.

Spinal Modulation is also backed by industry titans such as Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ), according to a company statement.

Filed Under: Neuromodulation/Neurostimulation, News Well, Pain Management, Research & Development, Spine Tagged With: Clinical Trials, Spinal Modulation, stjudemedical

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy